A multicenter retrospective cohort study conducted in Saudi Arabia found no significant impact on mortality reduction or ICU treatment [16], whereas an observational meta-analysis reported that DPP-4 inhibitor use reduced COVID-19-related mortality by approximately 50% [17]. Here, DPP4 is linked to COVID-19.